vs
Pacira BioSciences, Inc.（PCRX）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是COMSCORE, INC.的1.9倍（$177.4M vs $93.5M），COMSCORE, INC.净利率更高（3.2% vs 1.6%，领先1.6%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -1.5%），过去两年COMSCORE, INC.的营收复合增速更高（3.8% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
PCRX vs SCOR — 直观对比
营收规模更大
PCRX
是对方的1.9倍
$93.5M
营收增速更快
PCRX
高出6.6%
-1.5%
净利率更高
SCOR
高出1.6%
1.6%
两年增速更快
SCOR
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $93.5M |
| 净利润 | $2.9M | $3.0M |
| 毛利率 | — | 41.0% |
| 营业利润率 | 3.9% | 7.0% |
| 净利率 | 1.6% | 3.2% |
| 营收同比 | 5.0% | -1.5% |
| 净利润同比 | — | -3.7% |
| 每股收益（稀释后） | $0.07 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXSCOR
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $93.5M | ||
| Q3 25 | $179.5M | $88.9M | ||
| Q2 25 | $181.1M | $89.4M | ||
| Q1 25 | $168.9M | $85.7M | ||
| Q4 24 | $187.3M | $94.9M | ||
| Q3 24 | $168.6M | $88.5M | ||
| Q2 24 | $178.0M | $85.8M |
净利润PCRXSCOR
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $3.0M | ||
| Q3 25 | $5.4M | $453.0K | ||
| Q2 25 | $-4.8M | $-9.5M | ||
| Q1 25 | $4.8M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $-143.5M | $-60.6M | ||
| Q2 24 | $18.9M | $-1.7M |
毛利率PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 41.0% | ||
| Q3 25 | 80.9% | 40.6% | ||
| Q2 25 | 77.4% | 40.6% | ||
| Q1 25 | 79.7% | 39.6% | ||
| Q4 24 | 78.7% | 42.4% | ||
| Q3 24 | 76.9% | 41.2% | ||
| Q2 24 | 75.1% | 39.5% |
营业利润率PCRXSCOR
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 7.0% | ||
| Q3 25 | 3.5% | 1.9% | ||
| Q2 25 | 4.7% | -1.9% | ||
| Q1 25 | 1.2% | -2.4% | ||
| Q4 24 | 13.2% | 4.1% | ||
| Q3 24 | -82.8% | -67.4% | ||
| Q2 24 | 15.9% | -2.2% |
净利率PCRXSCOR
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 3.2% | ||
| Q3 25 | 3.0% | 0.5% | ||
| Q2 25 | -2.7% | -10.6% | ||
| Q1 25 | 2.8% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -85.1% | -68.5% | ||
| Q2 24 | 10.6% | -2.0% |
每股收益（稀释后）PCRXSCOR
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $9.50 | ||
| Q3 25 | $0.12 | $-0.86 | ||
| Q2 25 | $-0.11 | $-2.73 | ||
| Q1 25 | $0.10 | $-1.66 | ||
| Q4 24 | $0.38 | $-0.47 | ||
| Q3 24 | $-3.11 | $-12.79 | ||
| Q2 24 | $0.39 | $-1.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $23.6M |
| 总债务越低越好 | — | $41.5M |
| 股东权益账面价值 | $653.9M | $111.4M |
| 总资产 | $1.2B | $407.7M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资PCRXSCOR
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $23.6M | ||
| Q3 25 | $246.3M | $26.7M | ||
| Q2 25 | $445.9M | $26.0M | ||
| Q1 25 | $493.6M | $31.0M | ||
| Q4 24 | $484.6M | $29.9M | ||
| Q3 24 | $453.8M | $20.0M | ||
| Q2 24 | $404.2M | $14.7M |
总债务PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $41.5M | ||
| Q3 25 | $376.7M | $41.4M | ||
| Q2 25 | $580.5M | $41.3M | ||
| Q1 25 | $583.4M | $41.3M | ||
| Q4 24 | $585.3M | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXSCOR
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $111.4M | ||
| Q3 25 | $727.2M | $-26.3M | ||
| Q2 25 | $757.8M | $-21.7M | ||
| Q1 25 | $798.5M | $-13.5M | ||
| Q4 24 | $778.3M | $-8.3M | ||
| Q3 24 | $749.6M | $-2.7M | ||
| Q2 24 | $879.3M | $45.8M |
总资产PCRXSCOR
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $407.7M | ||
| Q3 25 | $1.3B | $406.9M | ||
| Q2 25 | $1.5B | $415.9M | ||
| Q1 25 | $1.6B | $421.5M | ||
| Q4 24 | $1.6B | $430.2M | ||
| Q3 24 | $1.5B | $412.5M | ||
| Q2 24 | $1.6B | $474.1M |
负债/权益比PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.37× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $2.9M |
| 自由现金流率自由现金流/营收 | — | 3.1% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.07× |
| 过去12个月自由现金流最近4个季度 | — | $21.8M |
8季度趋势，按日历期对齐
经营现金流PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $3.2M | ||
| Q3 25 | $60.8M | $9.5M | ||
| Q2 25 | $12.0M | $932.0K | ||
| Q1 25 | $35.5M | $9.1M | ||
| Q4 24 | $33.1M | $-10.0M | ||
| Q3 24 | $53.9M | $12.5M | ||
| Q2 24 | $53.2M | $8.7M |
自由现金流PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $2.9M | ||
| Q3 25 | $57.0M | $9.4M | ||
| Q2 25 | $9.3M | $787.0K | ||
| Q1 25 | $26.9M | $8.7M | ||
| Q4 24 | $31.0M | $-10.3M | ||
| Q3 24 | $49.8M | $12.4M | ||
| Q2 24 | $51.6M | $8.5M |
自由现金流率PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 3.1% | ||
| Q3 25 | 31.7% | 10.5% | ||
| Q2 25 | 5.1% | 0.9% | ||
| Q1 25 | 15.9% | 10.1% | ||
| Q4 24 | 16.6% | -10.8% | ||
| Q3 24 | 29.6% | 14.0% | ||
| Q2 24 | 29.0% | 10.0% |
资本支出强度PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 2.2% | 0.1% | ||
| Q2 25 | 1.5% | 0.2% | ||
| Q1 25 | 5.1% | 0.4% | ||
| Q4 24 | 1.1% | 0.2% | ||
| Q3 24 | 2.4% | 0.1% | ||
| Q2 24 | 0.9% | 0.2% |
现金转化率PCRXSCOR
| Q1 26 | — | — | ||
| Q4 25 | — | 1.07× | ||
| Q3 25 | 11.20× | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
